Liver cancer

Can-Fite BioPharma has concluded preparations for its Phase 2 trial evaluating namodenoson (CF102) for the treatment of non-alcoholic fatty liver disease (NAFLD). The study will…

Researchers at the National University of Singapore have developed a probe that provides doctors with clearer and more accurate magnetic resonance images of liver cancer.

Patients with advanced, inoperable hepatocellular carcinoma (HCC) may highly benefit from Immunitor‘s new oral immunotherapeutic vaccine, Hepko-V5 (hepcortespenlisimut-L), according to results of a Phase 2 trial.

The U.S. Food and Drug Administration (FDA) approved the use of Stivarga (regorafinib) for the treatment of patients with hepatocellular carcinoma (HCC), a form of…

Radiation-delivering microspheres developed by Sirtex are as effective as Nexavar (sorafenib) chemotherapy against a liver cancer known as hepatocellular carcinoma (HCC), according to a Phase 3…

NV556 inhibited tumor growth in mice with a liver disease known as non-alcoholic steatohepatitis, or NASH, according to a study by its maker, NeuroVive Pharmaceutical AB.

Bozitinib (CBT-101) suppresses the growth of human liver tumors in a laboratory environment, according to its maker, CBT Pharmaceuticals. The oral therapy works by…

A relative of a veterinary de-worming pill, in combination with the standard treatment Nexavar (sorafenib), was found to halt the growth of hepatocellular cancer (HCC) in laboratory…

A subset of stem cell-derived immune cells, known as iPS-ML, stopped tumor progression and improved survival of mice with liver cancer, a Japanese study showed.

The transforming growth factor-beta (TGF-beta) protein promotes the conversion of normal liver cells to cancerous cells, a study indicates. It also regulates liver cancer cells’ ability to…